These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 17109312)
1. Buprenorphine and HIV primary care: report of a forum for collaborative HIV research workshop. Miller V; Clin Infect Dis; 2006 Dec; 43 Suppl 4():S254-7. PubMed ID: 17109312 [TBL] [Abstract][Full Text] [Related]
2. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Schackman BR; Merrill JO; McCarty D; Levi J; Lubinski C Clin Infect Dis; 2006 Dec; 43 Suppl 4():S247-53. PubMed ID: 17109311 [TBL] [Abstract][Full Text] [Related]
3. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306 [TBL] [Abstract][Full Text] [Related]
4. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL; J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597 [TBL] [Abstract][Full Text] [Related]
5. Buprenorphine and HIV primary care: new opportunities for integrated treatment. Khalsa J; Vocci F; Altice F; Fiellin D; Miller V Clin Infect Dis; 2006 Dec; 43 Suppl 4():S169-72. PubMed ID: 17109302 [TBL] [Abstract][Full Text] [Related]
7. Patient perspectives of an integrated program of medical care and substance use treatment. Drainoni ML; Farrell C; Sorensen-Alawad A; Palmisano JN; Chaisson C; Walley AY AIDS Patient Care STDS; 2014 Feb; 28(2):71-81. PubMed ID: 24428768 [TBL] [Abstract][Full Text] [Related]
8. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Altice FL; Sullivan LE; Smith-Rohrberg D; Basu S; Stancliff S; Eldred L Clin Infect Dis; 2006 Dec; 43 Suppl 4():S178-83. PubMed ID: 17109304 [TBL] [Abstract][Full Text] [Related]
9. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. Schackman BR; Leff JA; Botsko M; Fiellin DA; Altice FL; Korthuis PT; Sohler N; Weiss L; Egan JE; Netherland J; Gass J; Finkelstein R; J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S76-82. PubMed ID: 21317599 [TBL] [Abstract][Full Text] [Related]
10. Expanding treatment for opioid use disorder in publicly funded primary care clinics: Exploratory evaluation of the NYC health + hospitals buprenorphine ECHO program. Tofighi B; Isaacs N; Byrnes-Enoch H; Lakew R; Lee JD; Berry C; Schatz D J Subst Abuse Treat; 2019 Nov; 106():1-3. PubMed ID: 31540604 [TBL] [Abstract][Full Text] [Related]
11. Ryan White CARE Act Title IV programs: a preliminary characterization of benefits and costs. Abramowitz S; Greene D AIDS Public Policy J; 2005; 20(3-4):108-25. PubMed ID: 17624034 [TBL] [Abstract][Full Text] [Related]
12. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study. Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467 [TBL] [Abstract][Full Text] [Related]
13. Models for integrating buprenorphine therapy into the primary HIV care setting. Basu S; Smith-Rohrberg D; Bruce RD; Altice FL Clin Infect Dis; 2006 Mar; 42(5):716-21. PubMed ID: 16447120 [TBL] [Abstract][Full Text] [Related]
14. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. Cheever LW; Kresina TF; Cajina A; Lubran R J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S3-6. PubMed ID: 21317591 [TBL] [Abstract][Full Text] [Related]
15. Service Delivery and Patient Outcomes in Ryan White HIV/AIDS Program-Funded and -Nonfunded Health Care Facilities in the United States. Weiser J; Beer L; Frazier EL; Patel R; Dempsey A; Hauck H; Skarbinski J JAMA Intern Med; 2015 Oct; 175(10):1650-9. PubMed ID: 26322677 [TBL] [Abstract][Full Text] [Related]
16. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Turner BJ; Laine C; Lin YT; Lynch K Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826 [TBL] [Abstract][Full Text] [Related]
17. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Sullivan LE; Fiellin DA Clin Infect Dis; 2005 Sep; 41(6):891-6. PubMed ID: 16107991 [TBL] [Abstract][Full Text] [Related]
18. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434 [TBL] [Abstract][Full Text] [Related]
19. Costs of care for persons with opioid dependence in commercial integrated health systems. Lynch FL; McCarty D; Mertens J; Perrin NA; Green CA; Parthasarathy S; Dickerson JF; Anderson BM; Pating D Addict Sci Clin Pract; 2014 Aug; 9(1):16. PubMed ID: 25123823 [TBL] [Abstract][Full Text] [Related]
20. Ryan White Title I Survey: services for HIV-positive substance users. Tobias C; Wood S; Drainoni ML AIDS Patient Care STDS; 2006 Jan; 20(1):58-67. PubMed ID: 16426157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]